Advancing Evidence in Dolutegravir/Lamivudine (DTG/3TC) Treatment (General)

ViiV Healthcare welcomes investigator-sponsored research that advances understanding of DTG/3TC in the treatment of HIV. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, and health-related quality of life. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.

ViiV ISR Area Of Interest Overview

Drug/Product Alignment

ViiV Products in Scope:	Dolutegravir
Treatment Type:	Treatment
Specify the Treatment Type:

Area of Interest/DataGap Description

Core Focus Area:	Open
Example Research Question(s):	All scientifically sound and relevant research questions that advance evidence in DTG/3TC treatment are welcome.

Desirable Study Parameters

Populations of Interest:	All Patient Types
Geographical Regions:	Global

Version 20250909-disp

- Back to Top -

Advancing Evidence in Dolutegravir/Lamivudine (DTG/3TC) Treatment (General)

ViiV ISR Area Of Interest Overview

Pure Substance Request

Investigator Sponsored Study (ISS)

Collaborative Study